Mitochondrial Dysfunction in Blood Platelets of Patients with Manic Episode of Bipolar Disorder

Author(s): Jana Hroudová*, Zdeněk Fišar, Hana Hansíková, Lucie Kališová, Eva Kitzlerová, Martina Zvěřová, Alena Lambertová, Jiří Raboch .

Journal Name: CNS & Neurological Disorders - Drug Targets

Volume 18 , Issue 3 , 2019

Become EABM
Become Reviewer

Graphical Abstract:


Abstract:

Objectives: The bipolar affective disorder (BAD) pathophysiology is multifactorial and has not been fully clarified.

Method: We measured selected mitochondrial parameters in peripheral blood components. The analyses were performed for patients suffering from a manic episode during remission and were compared to those performed for healthy controls. BAD was clinically evaluated using well-established diagnostic scales and questionnaires. Mitochondrial respiration was examined in intact and permeabilized blood platelets using high-resolution respirometry. The citrate synthase (CS) and electron transport system (ETS) complex (complex I, II, and IV) activities were examined in platelets.

Results: The CS, complex II and complex IV activities were decreased in the BAD patients, complex I activity was increased, and the ratio of complex I to CS was significantly increased. In the intact platelets, respiration after complex I inhibition and residual oxygen consumption were decreased in the BAD patients compared to the healthy controls. In the permeabilized platelets, a decreased ETS capacity was found in the BAD patients. No significant differences were found between BAD patients in mania and remission.

Conclusion: Increased complex I activity can be a compensatory mechanism for decreased CS and complex II and IV activities. We conclude that complex I and its abnormal activity contribute to defects in cellular energy metabolism during a manic episode and that the deficiency in the complex's functioning, but not the availability of oxidative phosphorylation substrates, seems to be responsible for the decreased ETS capacity in BAD patients. The observed parameters can be further evaluated as ‘trait’ markers of BAD.

Keywords: Bipolar affective disorder, blood platelet, electron transport chain complexes, mania, mitochondrion, respiratory rate.

[1]
Malhi GS, Tanious M, M Berk. Mania: diagnosis and treatment recommendations. Curr Psychiatry Rep 2012; 14(6): 676-86.
[2]
Kato T. Mitochondrial DNA polymorphisms in bipolar disorder. J Affect Disord 2001; 62(3): 151-64.
[3]
Mazza M. Cariprazine in bipolar depression and mania: state of the art. CNS Neurol Disord Drug Targets 2018; 17(10): 723-7.
[4]
Amodeo G. Older and newer strategies for the pharmacological management of agitation in patients with bipolar disorder or schizophrenia. CNS Neurol Disord Drug Targets 2017; 16(8): 885-90.
[5]
Cikánková T. Mitochondrial dysfunctions in bipolar disorder: effect of the disease and pharmacotherapy. CNS and Neurol Disord Drug Targets 2017; 16(2): 176-86.
[6]
Vazquez GH. Potential novel treatments for bipolar depression: ketamine, fatty acids, anti-inflammatory agents, and probiotics. CNS Neurol Disord Drug Targets 2017; 16(8): 858-69.
[7]
Bavaresco DV. Efficacy of celecoxib adjunct treatment on bipolar disorder: systematic review and meta-analysis. CNS Neurol Disord Drug Target 2018. Doi: 10.2174/1871527317666181105162347
[8]
Berk M. Pathways underlying neuroprogression in bipolar disorder: focus on inflammation, oxidative stress and neurotrophic factors. Neurosci Biobehav Rev 2011; 35(3): 804-17.
[9]
Sigitova E. Biological hypotheses and biomarkers of bipolar disorder. Psychiatry Clin Neurosci 2017; 71(2): 77-103.
[10]
Shao L. Mitochondrial involvement in psychiatric disorders. Ann Med 2008; 40(4): 281-95.
[11]
Rezin GT. Mitochondrial dysfunction and psychiatric disorders. Neurochem Res 2009; 34(6): 1021-9.
[12]
Jou SH, Chiu NY, Liu CS. Mitochondrial dysfunction and psychiatric disorders. Chang Gung Med J 2009; 32(4): 370-9.
[13]
Schapira AH. Mitochondrial diseases. Lancet 2012; 379(9828): 1825-34.
[14]
Young LT. Is bipolar disorder a mitochondrial disease? J Psychiatry Neurosci 2007; 32(3): 160-1.
[15]
Clay HB, Sillivan S, Konradi C. Mitochondrial dysfunction and pathology in bipolar disorder and schizophrenia. Int J Dev Neurosci 2011; 29(3): 311-24.
[16]
Shevtsova EF. Mitochondrial permeability transition pore as a suitable target for neuroprotective agents against Alzheimer’s Disease. CNS Neurol Disord Drug Targets 2017; 16(6): 677-85.
[17]
Cikankova T. Mitochondrial dysfunctions in bipolar disorder: effect of the disease and pharmacotherapy. CNS Neurol Disord Drug Targets 2017; 16(2): 176-86.
[18]
Stork C, Renshaw PF. Mitochondrial dysfunction in bipolar disorder: evidence from magnetic resonance spectroscopy research. Mol Psychiatry 2005; 10(10): 900-19.
[19]
Quiroz JA. Mitochondrially mediated plasticity in the pathophysiology and treatment of bipolar disorder. Neuropsychopharmacology 2008; 33(11): 2551-65.
[20]
Kato T, Kato N. Mitochondrial dysfunction in bipolar disorder. Bipolar Disord 2000; 2(3 Pt 1): 180-90.
[21]
Kumar A. Autophagy and Mitochondria: targets in neurodegenerative disorders. CNS Neurol Disord Drug Targets 2018; 17(9): 696-705.
[22]
Yildiz-Yesiloglu A, Ankerst DP. Neurochemical alterations of the brain in bipolar disorder and their implications for pathophysiology: a systematic review of the in vivo proton magnetic resonance spectroscopy findings. Prog Neuropsychopharmacol Biol Psychiatry 2006; 30(6): 969-95.
[23]
de Sousa RT. Regulation of leukocyte tricarboxylic acid cycle in drug-naive Bipolar disorder. Neurosci Lett 2015; 605: 65-8.
[24]
Andreazza AC. Mitochondrial complex I activity and oxidative damage to mitochondrial proteins in the prefrontal cortex of patients with bipolar disorder. Arch Gen Psychiatry 2010; 67(4): 360-8.
[25]
Pesta D, Gnaiger E. High-resolution respirometry: OXPHOS protocols for human cells and permeabilized fibers from small biopsies of human muscle. Methods Mol Biol 2012; 810: 25-58.
[26]
Fox JE, Reynolds CC, Boyles JK. Studying the platelet cytoskeleton in Triton X-100 lysates. Methods Enzymol 1992; 215: 42-58.
[27]
Charles EF, Lambert CG, Kerner B. Bipolar disorder and diabetes mellitus: evidence for disease-modifying effects and treatment implications. Int J Bipolar Disord 2016; 4(1): 13.
[28]
Wu F. Platelet mitochondrial dysfunction of DM rats and DM patients. Int J Clin Exp Med 2015; 8(5): 6937-46.
[29]
Rustin P. Biochemical and molecular investigations in respiratory chain deficiencies. Clin Chim Acta 1994; 228(1): 35-51.
[30]
Srere SJ. Citrate synthase.[EC 4.1.3.7 Citrate oxaloacetate-lyase (CoA acetylating)] Methods Enzymol 1969; 13: 3-11.
[31]
Fisar Z. Mitochondrial respiration in the platelets of patients with Alzheimer’s disease. Curr Alzheimer Res 2016; 13(8): 930-41.
[32]
Hroudova J. Mitochondrial respiration in blood platelets of depressive patients. Mitochondrion 2013; 13(6): 795-800.
[33]
Diab YA. Acquired cytochrome C oxidase impairment in apheresis platelets during storage: a possible mechanism for depletion of metabolic adenosine triphosphate. Transfusion 2012; 52(5): 1024-30.
[34]
Renner K. Changes of mitochondrial respiration, mitochondrial content and cell size after induction of apoptosis in leukemia cells. Biochim Biophys Acta 2003; 1642(1-2): 115-23.
[35]
Stadlmann S. Preserved coupling of oxidative phosphorylation but decreased mitochondrial respiratory capacity in IL-1beta-treated human peritoneal mesothelial cells. Cell Biochem Biophys 2006; 44(2): 179-86.
[36]
Sjovall F. Temporal increase of platelet mitochondrial respiration is negatively associated with clinical outcome in patients with sepsis. Crit Care 2010; 14(6): R214.
[37]
R, Core Team, A language andenvironment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria. 2017
[38]
Sjovall F. Mitochondrial respiration in human viable platelets-methodology and influence of gender, age and storage. Mitochondrion 2013; 13(1): 7-14.
[39]
Wang L. Platelet mitochondrial dysfunction and the correlation with human diseases. Biochem Soc Trans 2017; 45(6): 1213-23.
[40]
Feier G. Lithium and valproate modulate energy metabolism in an animal model of mania induced by methamphetamine. Pharmacol Biochem Behav 2013; 103(3): 589-96.
[41]
Valvassori SS. Effects of mood stabilizers on mitochondrial respiratory chain activity in brain of rats treated with d-amphetamine. J Psychiatr Res 2010; 44(14): 903-9.
[42]
Freitas TP. Evaluation of citrate synthase activity in brain of rats submitted to an animal model of mania induced by ouabain. Mol Cell Biochem 2010; 341(1-2): 245-9.
[43]
Gubert C. Mitochondrial activity and oxidative stress markers in peripheral blood mononuclear cells of patients with bipolar disorder, schizophrenia, and healthy subjects. J Psychiatr Res 2013; 47(10): 1396-402.
[44]
Rollins BL. Mitochondrial complex I deficiency in schizophrenia and bipolar disorder and medication influence. Mol Neuropsychiatry 2018; 3(3): 157-69.
[45]
Bohm M. Activities of respiratory chain complexes in isolated platelets in females with anorexia nervosa. Int J Eat Disord 2007; 40(7): 659-63.
[46]
Ben-Shachar D. The interplay between mitochondrial complex I, dopamine and Sp1 in schizophrenia. J Neural Transm 2009; 116(11): 1383-96.
[47]
Hroudova J, Fisar Z. Connectivity between mitochondrial functions and psychiatric disorders. Psychiatry Clin Neurosci 2011; 65(2): 130-41.
[48]
de Sousa RT. Lithium increases leukocyte mitochondrial complex I activity in bipolar disorder during depressive episodes. Psychopharmacology 2015; 232(1): 245-50.
[49]
Hroudova J, Fisar Z. Activities of respiratory chain complexes and citrate synthase influenced by pharmacologically different antidepressants and mood stabilizers. Neuroendocrinol Lett 2010; 31(3): 336-42.
[50]
Hroudova J, Fisar Z. In vitro inhibition of mitochondrial respiratory rate by antidepressants. Toxicol Lett 2012; 213(3): 345-52.
[51]
Overall JE, Gorham DR. The brief psychiatric rating scale. Psychol Rep 1962; 10: 799-812.
[52]
Guy W. Clinical Global Impressions (CGI) Scale, modified. In: Rush, John A; Task Force for the Handbook of Psychiatric Measures Handbook of Psychiatric Measures. 1st ed. 2000: Washington D.C., American Psychiatric Association.
[53]
Lukasiewicz M. Young mania rating scale: how to interpret the numbers? Determination of a severity threshold and of the minimal clinically significant difference in the EMBLEM cohort. Int J Methods Psychiatr Res 2013; 22(1): 46-58.


Rights & PermissionsPrintExport Cite as

Article Details

VOLUME: 18
ISSUE: 3
Year: 2019
Page: [222 - 231]
Pages: 10
DOI: 10.2174/1871527318666181224130011
Price: $58

Article Metrics

PDF: 29
HTML: 1